Literature DB >> 21258035

Predicting the risk for dialysis or death in IgA nephropathy.

François Berthoux1, Hesham Mohey, Blandine Laurent, Christophe Mariat, Aida Afiani, Lise Thibaudin.   

Abstract

For the individual patient with primary IgA nephropathy (IgAN), it remains a challenge to predict long-term outcomes for patients receiving standard treatment. We studied a prospective cohort of 332 patients with biopsy-proven IgAN patients followed over an average of 13 years. We calculated an absolute renal risk (ARR) of dialysis or death by counting the number of risk factors present at diagnosis: hypertension, proteinuria ≥1 g/d, and severe pathologic lesions (global optical score, ≥8). Overall, the ARR score allowed significant risk stratification (P < 0.0001). The cumulative incidence of death or dialysis at 10 and 20 years was 2 and 4%, respectively, for ARR=0; 2 and 9% for ARR=1; 7 and 18% for ARR=2; and 29 and 64% for ARR=3, in adequately treated patients. When achieved, control of hypertension and reduction of proteinuria reduced the risk for death or dialysis. In conclusion, the absolute renal risk score, determined at diagnosis, associates with risk for dialysis or death.
Copyright © 2011 by the American Society of Nephrology

Entities:  

Mesh:

Year:  2011        PMID: 21258035      PMCID: PMC3065230          DOI: 10.1681/ASN.2010040355

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  44 in total

1.  Predicting prognosis in IgA nephropathy.

Authors:  J Feehally
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

2.  Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis.

Authors:  F Bonnet; C Deprele; A Sassolas; P Moulin; E Alamartine; F Berthezène; F Berthoux
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

Review 3.  IgA nephropathy.

Authors:  James V Donadio; Joseph P Grande
Journal:  N Engl J Med       Date:  2002-09-05       Impact factor: 91.245

4.  Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

Authors:  D Russo; R Minutolo; A Pisani; R Esposito; G Signoriello; M Andreucci; M M Balletta
Journal:  Am J Kidney Dis       Date:  2001-07       Impact factor: 8.860

5.  Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.

Authors:  Y Kanno; H Okada; T Saruta; H Suzuki
Journal:  Clin Nephrol       Date:  2000-11       Impact factor: 0.975

6.  Predicting progression in IgA nephropathy.

Authors:  L P Bartosik; G Lajoie; L Sugar; D C Cattran
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

7.  Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives.

Authors:  Philip Kam Tao Li; Kelvin Kai Leung Ho; Cheuk Chun Szeto; LyMee Yu; Fernand Mac-Moune Lai
Journal:  Nephrol Dial Transplant       Date:  2002-01       Impact factor: 5.992

8.  Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy.

Authors:  J Syrjänen; J Mustonen; A Pasternack
Journal:  Nephrol Dial Transplant       Date:  2000-01       Impact factor: 5.992

9.  Histopathologic features aid in predicting risk for progression of IgA nephropathy.

Authors:  Michael Walsh; Aylin Sar; Diane Lee; Serdar Yilmaz; Hallgrimur Benediktsson; Braden Manns; Brenda Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

10.  Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.

Authors:  James V Donadio; Erik J Bergstralh; Joseph P Grande; Diana M Rademcher
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

View more
  123 in total

1.  Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.

Authors:  Yusuke Okabayashi; Nobuo Tsuboi; Kotaro Haruhara; Go Kanzaki; Kentaro Koike; Akihiro Shimizu; Yoichi Miyazaki; Iwao Ohno; Tetsuya Kawamura; Makoto Ogura; Takashi Yokoo
Journal:  Clin Exp Nephrol       Date:  2016-02-01       Impact factor: 2.801

2.  Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

Authors:  Aron Chakera; Clare MacEwen; Shubha S Bellur; La-Or Chompuk; Daniel Lunn; Ian S D Roberts
Journal:  J Nephrol       Date:  2015-08-30       Impact factor: 3.902

3.  [Acute, bilateral visual loss in a patient with IgA glomerulonephritis].

Authors:  J Ehrhardt; F Gelisken
Journal:  Ophthalmologe       Date:  2018-03       Impact factor: 1.059

Review 4.  Corticosteroid therapy in IgA nephropathy.

Authors:  Jicheng Lv; Damin Xu; Vlado Perkovic; Xinxin Ma; David W Johnson; Mark Woodward; Adeera Levin; Hong Zhang; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

Review 5.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

6.  Reliability and Utility of the Surprise Question in CKD Stages 4 to 5.

Authors:  Andrei D Javier; Rocio Figueroa; Edward D Siew; Huzaifah Salat; Jennifer Morse; Thomas G Stewart; Rakesh Malhotra; Manisha Jhamb; Jane O Schell; Cesar Y Cardona; Cathy A Maxwell; T Alp Ikizler; Khaled Abdel-Kader
Journal:  Am J Kidney Dis       Date:  2017-02-15       Impact factor: 8.860

7.  Development and validation of a prediction rule using the Oxford classification in IgA nephropathy.

Authors:  Shigeru Tanaka; Toshiharu Ninomiya; Ritsuko Katafuchi; Kosuke Masutani; Akihiro Tsuchimoto; Hideko Noguchi; Hideki Hirakata; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

8.  Update on immunoglobulin A nephropathy, Part I: Pathophysiology.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2015-09-06

9.  Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kandai Nozu; Kazumoto Iijima; Yuko Shima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2014-12-10       Impact factor: 3.714

10.  Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.

Authors:  Francois Berthoux; Hitoshi Suzuki; Lise Thibaudin; Hiroyuki Yanagawa; Nicolas Maillard; Christophe Mariat; Yasuhiko Tomino; Bruce A Julian; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.